AUL
BMRN icon

AlphaGrep UK Ltd’s BioMarin Pharmaceuticals BMRN Stock Holding History

AlphaGrep UK Ltd’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$266K Buy
+4,706
New +$274K 0.08% 568

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaGrep UK Ltd's BMRN Position: Q1 2026 in Review

AlphaGrep UK Ltd opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 4,706 shares worth $266K. The stake represents 0.08% of the portfolio and ranks #568 among its holdings.

557 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • AlphaGrep UK Ltd held 4,706 shares of BioMarin Pharmaceuticals worth $266K as of Q1 2026.
  • BioMarin Pharmaceuticals was a new AlphaGrep UK Ltd position in Q1 2026.
  • BioMarin Pharmaceuticals made up 0.08% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #568 holding.
  • 557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.